An open-label phase 1/2a study of the safety and efficacy of melflufen and dexamethasone in combination with either bortezomib or daratumumab in patients with relapsed or relapsed-refractory multiple myeloma (ANCHOR). NCT03481556
Attal M et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 2017;376(14):1311-20. Abstract
Avet-Loiseau H et al. Efficacy of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial. Proc ASCO 2019;Abstract 8017.
Bringhen S et al. Analysis of time to next treatment (TTNT) in melflufen and dexamethasone-treated patients (pts) with relapsed/refractory multiple myeloma (RRMM). Proc ASCO 2019;Abstract 8043.
Chari A et al. Results of the pivotal STORM study (Part 2) in penta-refractory multiple myeloma (MM): Deep and durable responses with oral selinexor plus low dose dexamethasone in patients with penta-refractory MM. Proc ASH 2018;Abstract 598.
Chen C et al. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. Blood 2018;131(8):855-63. Abstract
Dimopoulos MA et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): A double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2019;393(10168):253-64. Abstract
Facon T et al. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 2019;133(18):1953-63. Abstract
Facon T et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019;380(22):2104-15. Abstract
Gay F et al. Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial. Proc ASCO 2019;Abstract 8002.
Kumar S et al. A phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Proc EHA 2019;Abstract LB2601.
Kumar S et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood 2017;130(22):2401-9. Abstract
Lee DW et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25(4):625-38. Abstract
Lonial S et al. E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma. Proc ASCO 2019;Abstract 8001.
Mateos MV et al. Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA. ASCO 2019;Abstract 8005.
Moreau P et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study. Lancet 2019;394(10192):29-38. Abstract
Moreau P et al. Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results. ASCO 2019;Abstract 8003.
Moreau P et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood 2017;130(22):2392-400. Abstract
Moreau P et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;374(17):1621-34. Abstract
Ocio EM et al. Preliminary results from a phase I study of isatuximab (ISA) in combination with bortezomib, lenalidomide, dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM) non-eligible for transplant. Proc ASH 2018;Abstract 595.
Pour L et al. ANCHOR (OP‑104): A phase 1 study update of melflufen and dexamethasone plus bortezomib or daratumumab in relapsed/refractory multiple myeloma patients refractory to an IMiD or a proteasome inhibitor. Proc EHA 2019;Abstract PF608.
Raje N et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med 2019;380(18):1726-37. Abstract
Richardson PG et al. A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). ASCO 2019;Abstract 8004.
Richardson PG et al. HORIZON (OP 106): Updated efficacy and safety of melflufen in relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (DARA) and/or pomalidomide. Proc EHA 2019;Abstract S1605.
Richardson PG et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): A randomised, open-label, phase 3 trial. Lancet Oncol 2019;20(6):781-94. Abstract
Richardson P et al. OP-106 Horizon — melflufen therapy for RRMM patients refractory to daratumumab and/or pomalidomide; updated results and first report on PFS. Proc ASH 2018;Abstract 600.
San Miguel J et al. Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. ASCO 2019;Abstract 8000.
Topp MS et al. Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study. Proc ASCO 2019;Abstract 8007.
Trudel S et al. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study. Blood Cancer J 2019;9(4):37. Abstract
Usmani SZ et al. Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA. ASCO 2019;Abstract 8035.
Varga C et al. Current use of monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol 2018;181(4):447-59. Abstract
Vogl DT et al. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol 2018;36(9):859-66. Abstract
Voorhees PM et al. Efficacy and updated safety analysis of a safety run-in cohort from Griffin, a phase 2 randomized study of daratumumab (Dara), bortezomib (V), lenalidomide (R), and dexamethasone (D; Dara‐VRd) vs VRd in patients with newly diagnosed multiple myeloma eligible for high‐dose therapy and autologous stem cell transplantation. Proc ASH 2018;Abstract 151.